
Game-changing cholesterol pill wins FDA approval after cutting LDL nearly 60%
- FDA approves Lipfendra, first oral PCSK9 inhibitor for cholesterol
- Merck's daily pill can cut LDL cholesterol by nearly 60%
- Offers needle-free alternative to existing injectable PCSK9 treatments
The US Food and Drug Administration has approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, giving millions of Americans with high cholesterol a new pill-based treatment option. Manufactured by Merck, the drug offers an alternative to existing PCSK9 inhibitors, which have previously only been available as injections,…






